43 unchanged sentences
We have adopted a written Code of Business Conduct and Ethics (Code of Conduct) that applies to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions.
−Removed: The Code of Conduct is available on our website at www.chromadex.com.
+Added: The Code of Conduct is available on our website at www.niagenbioscience.com.
If we make any substantive amendments to the Code of Conduct or grant any waiver from a provision of the Code of Conduct to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website in lieu of filing such waiver or amendment in a Current Report on Form 8-K.
6 unchanged sentences
Principal Accountant Fees and Services
−Removed: Marcum LLP served as our independent registered public accounting firm from January 1, 2024 to October 31, 2024.
−Removed: Effective December 13, 2024, Crowe LLP, Audit Firm ID:
−Removed: 173, is our independent registered public accounting firm.
+Added: Our independent registered public accounting firm is Crowe LLP, Audit Firm ID:
The information required by this item is to be included in our Proxy Statement under the caption “Ratification of the Appointment of Independent Registered Public Accounting Firm” and is incorporated herein by reference.
6 unchanged sentences
INDEX TO EXHIBITS
−Removed: Incorporated by Reference Filed or
−Removed: Description Form File Number Exhibit Filing Date
+Added: Incorporated by Reference
+Added: Description Form File Number Exhibit Filing Date Filed or
2.1 Agreement and Plan of Merger, dated as of May 21, 2008, among Cody, CDI Acquisition, Inc.
4 unchanged sentences
10-K 001-37752 3.1 3/15/2018
−Removed: 3.2 Certificate of Amendment to the Certificate of Incorporation of the Registrant
−Removed: 8-K 001-37752 3.1 4/12/2016
−Removed: Incorporated by Reference Filed or
−Removed: Description Form File Number Exhibit Filing Date
−Removed: 3.3 Amended and Restated Bylaws of the Registrant
+Added: 3.2 Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation
8-K 000-53290 3.1 3/19/2025
−Removed: 4.1 Form of Stock Certificate representing shares of the Registrant’s Common Stock effective as of December 10, 2018
+Added: Incorporated by Reference
+Added: Description Form File Number Exhibit Filing Date Filed or
+Added: 3.3 Amended and Restated By laws of Niagen Bioscience, Inc.
8-K 000-53290 3.2 3/19/2025
+Added: 4.1 Form of Stock Certificate representing shares of the Registrant’s Common Stock
+Added: 10-Q 001-37752 4.1 5/7/2025
4.2 Description of Common Stock of the Registrant
10 unchanged sentences
DEF 14A 000-53290 Appendix B 5/4/2010
−Removed: 10.2 Form of Stock Option Agreement under the ChromaDex, Inc.
+Added: 10.2 Form of Stock Option Agreement under the Ch romaDex , Inc .
Second Amended and Restated 2007 Equity Incentive Plan(1)+
3 unchanged sentences
8-K 333-140056 10.4 6/24/2008
−Removed: 10.4 ChromaDex Corporation 2017 Equity Incentive Plan, as amended +
+Added: 10.4 Niagen Bioscience, Inc.
+Added: 2017 Equity Incentive Plan, as amended +
8-K 001-37752 10.1 6/27/2025
+Added: 10.5 Form of Stock Option Agreement under Niagen Bioscience, Inc.
+Added: 2017 Equity Incentive Plan, as amended +
+Added: 10-Q 001-37752 10.6 5/7/2025
+Added: 10.6 Form of Restricted Stock Purchase Agreement under the Niagen Bioscience, Inc.
+Added: 2017 Equity Incentive Plan, as amended
+Added: 10-Q 001-37752 10.7 5/7/2025
+Added: 10.7 Niagen Bioscience, Inc.
+Added: Employee Stock Purchase Plan +
+Added: 8-K 001-37752 10.2 6/27/2025
+Added: 10.8 First Amendment to Niagen Bioscience, Inc.
+Added: Employee Stock Purchase Plan, as amended +
10.9 Amended and Restated Employment Agreement dated April 19, 2010, by and between Frank L.
−Removed: and ChromaDex, Inc.
+Added: and C hromaDex , Inc.
8-K 000-53290 10.1 4/22/2010
11.0 Amendment, dated June 22, 2018, to the Amended and Restated Employment Agreement, by and between Frank L.
−Removed: and ChromaDex, Inc.
+Added: and C hromaDex , Inc.
8-K 001-37752 10.2 6/28/2018
8 unchanged sentences
10-Q 001-37752 10.7 11/10/2016
+Added: Incorporated by Reference
+Added: Description Form File Number Exhibit Filing Date Filed or
10.11 Lease Agreement, made as of April 14, 2016, by and between Longmont Diagonal Investments LLC and ChromaDex Analytics, Inc.
4 unchanged sentences
10-Q 001-37752 10.8 11/4/2020
−Removed: 10.13 Form of Indemnity Agreement, between the Registrant and each of its existing directors and executive officers +
−Removed: 8-K 001-37752 10.1 12/16/2016
−Removed: 10.14 Amended and Restated Non-Employee Director Compensation Policy +
+Added: 10.13 Second Amendment to Lease Agreement, dated March 11 2025, by and between ChromaDex Analytics, Inc.
+Added: and 62 1625-1751 S.
+Added: Fordham LLC and 64 1625-1751 S.
10-Q 001-37752 10.3 5/7/2025
−Removed: Incorporated by Reference Filed or
−Removed: Description Form File Number Exhibit Filing Date
+Added: 10.14 Form of Indemnity Agreement, between the Registrant and each of its existing directors and executive officers +
10.15 Form of Restricted Stock Award Agreement for Robert Fried +
8 unchanged sentences
10-K 001-37752 10.50 3/7/2019
−Removed: 10.20 First Amendment to Lease, dated February 7, 2018, by and between 10900 WILSHIRE L.L.C and ChromaDex, Inc.
+Added: 10.20 First Amendment to Lease, dated February 7, 2018, by and between 10900 WILSHIRE L.L.C and C hromaDex , Inc.
10-K 001-37752 10.51 3/7/2019
19 unchanged sentences
S-3 333-237144 1.2 6/12/2020
+Added: Incorporated by Reference
+Added: Description Form File Number Exhibit Filing Date Filed or
10.30 Amendment No.
7 unchanged sentences
10-K 001-37752 10.42 3/14/2022
−Removed: Incorporated by Reference Filed or
−Removed: Description Form File Number Exhibit Filing Date
10.34 Consent to Business Financing Agreement, dated January 14, 2021, by and among Western Alliance Bank and ChromaDex Corporation
11 unchanged sentences
and ChromaDex Analytics, Inc.
+Added: 10-K 001-37752 10.38 3/4/2025
+Added: 10.39 Seventh Modification to Business Financing Agreement dated March 24 , 202 5 by and among Western Alliance Bank, Niagen Bioscience, Inc., ChromaDex, Inc.
+Added: and ChromaDex Analytics, Inc.
+Added: 10-Q 001-37752 10.4 5/7/2025
+Added: 10.40 Eig hth Modification to Business Financing Agreement dated November 12 , 2025 by and among Western Alliance Bank, Niagen Bioscience, Inc., ChromaDex, Inc.
+Added: and ChromaDex Analytics, Inc.
10.41 Manufacturing and Supply Agreement, dated as of January 1, 2016, by and between ChromaDex , Inc.
13 unchanged sentences
10-Q 001-37752 10.5 11/4/2020
+Added: Incorporated by Reference
+Added: Description Form File Number Exhibit Filing Date Filed or
10.46 Fifth Amendment to Manufacturing and Supply Agreement, dated as of January 1, 2020, by and between ChromaDex , Inc.
4 unchanged sentences
10-Q 001-37752 10.7 11/4/2020
−Removed: 10.46 Seventh Amendment to Manufacturing and Supply Agreement, dated as of August 2, 2021, by and between ChromaDex Inc.
+Added: 10.48 Seventh Amendment to Manufacturing and Supply Agreement, dated as of August 2, 2021, by and between C hromaDex , Inc.
Grace & Co.-Conn.
6 unchanged sentences
10-Q 001-37752 10.3 11/8/2023
−Removed: Incorporated by Reference Filed or
−Removed: Description Form File Number Exhibit Filing Date
10.51 Tenth Amendment to Manufacturing and Supply Agreement, dated as of January 1, 2025, by and between ChromaDex Inc.
1 unchanged sentence
10-Q 001-37752 10.2 10/31/2024
+Added: 10.52 Sales Agreement, dated July 25, 2025, by and between ChromaDex, Inc.
+Added: Grace & Co.-Conn.
+Added: 8-K 001-37752 10.1 7/29/2025
10.53 Exclusive License Agreement, dated September 8, 2011, by and between ChromaDex , Inc.
1 unchanged sentence
10-Q 001-37752 10.1 11/3/2021
−Removed: 10.51 Lease, dated November 24, 2021, by and between Flight Phase I Owner, LLC and ChromaDex Corporation
+Added: 10.54 Lease, dated November 24, 2021, by and between Flight Phase I Owner, LLC and C hromaDex Corporation
10-K 001-37752 10.59 3/14/2022
3 unchanged sentences
10-Q 001-37752 10.6 5/12/2022
+Added: 10.57 Assignment Agreement, dated December 18, 2025, by and between ChromaDex , Inc.
+Added: and Queen’s University Belfast**
+Added: 8-K 001-37752 10.1 12/22/2025
10.58 Securities Purchase Agreement, dated September 30, 2022, by and among the Company and the Purchasers
6 unchanged sentences
8-K 001-37752 10.1 6/25/2024
+Added: 10.62 Amended and Restated Non-Employee Director Compensation Policy +
+Added: 10-Q 001-37752 10.8 5/7/2025
+Added: Incorporated by Reference
+Added: Description Form File Number Exhibit Filing Date Filed or
10.63 Amended and Restated Incentive Compensation Recoupment Policy +
−Removed: 10-K 001-37752 10.60 3/6/2024
+Added: 10-Q 001-37752 10.9 5/7/2025
10.64 Offer Letter, dated September 10, 2024, by and between Ozan Pamir and ChromaDex, Inc.
8-K 001-37752 10.1 9/20/2024
−Removed: 10.60 Offer Letter, dated June 27, 2024, by and between Carlos Lopez and ChromaDex, Inc.
−Removed: 16.1 Letter from Marcum LLP, dated as of October 11, 2024, addressed to the Securities and Exchange Commission
+Added: 10.65 Offer Letter, dated June 27, 2024, by and between Carlos Lopez and Chro maDex , Inc.
8-K 001-37752 10.60 3/4/2025
19.1 Insider Trading Policy
−Removed: Subsidiaries of ChromaDex Corporation
+Added: Subsidiaries of Niagen Bioscience, Inc.
Consent of Crowe, LLP, Independent Registered Public Accounting Firm
−Removed: 23.2 Consent of Marcum, LLP, Independent Registered Public Accounting Firm
24.1 Power of Attorney (included on the signature page of this Annual Report on Form 10-K) X
4 unchanged sentences
97.1 Dodd-Frank Clawback Policy +
−Removed: 10-K 001-37752 97.1 3/6/2024
−Removed: Incorporated by Reference Filed or
−Removed: Description Form File Number Exhibit Filing Date
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
5 unchanged sentences
104 Cover Page Interactive Data File - formatted in Inline XBRL and included in Exhibit 101
−Removed: (1) Plan and related Forms were assumed by ChromaDex Corporation pursuant to Agreement and Plan of Merger, dated as of May 21, 2008, among ChromaDex Corporation (formerly Cody Resources, Inc.), CDI Acquisition, Inc.
+Added: (1) Plan and related Forms were assumed by Niagen Bioscience, Inc.
+Added: pursuant to Agreement and Plan of Merger, dated as of May 21, 2008, among Niagen Bioscience, Inc.
+Added: (formerly ChromaDex Corporation), Cody Resources, Inc., CDI Acquisition, Inc.
and ChromaDex, Inc.
(2) Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
−Removed: ChromaDex Corporation undertakes to furnish supplemental copies of any of the omitted schedules upon request by the Securities and Exchange Commission;
−Removed: provided, however, that ChromaDex Corporation may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule so furnished.
+Added: Niagen Bioscience, Inc.
+Added: undertakes to furnish supplemental copies of any of the omitted schedules upon request by the Securities and Exchange Commission;
+Added: provided, however, that Niagen Bioscience, Inc.
+Added: may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule so furnished.
+ Indicates management contract or compensatory plan or arrangement.
4 unchanged sentences
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: CHROMADEX CORPORATION
+Added: NIAGEN BIOSCIENCE, INC.
/s/ ROBERT FRIED
20 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.